Mycobacterium tuberculosis Drug Resistance in Ethiopia: An Updated Systematic Review and Meta-Analysis

Abstract

Background: Tuberculosis (TB) remains a significant global public health issue, despite advances in diagnostic technologies, substantial global efforts, and the availability of effective chemotherapies. Mycobacterium tuberculosis, a species of pathogenic bacteria resistant to currently available anti-TB drugs, is on the rise, threatening national and international TB-control efforts. This systematic review and meta-analysis aims to estimate the pooled prevalence of drug-resistant TB (DR-TB) in Ethiopia. Materialsand Methods: A systematic literature search was undertaken using PubMed/MEDLINE, HINARI, the Web of Science, ScienceDirect electronic databases, and Google Scholar (1 January 2011 to 30 November 2020). After cleaning and sorting the records, the data were analyzed using STATA 11. The study outcomes revealed the weighted pooled prevalence of any anti-tuberculosis drug resistance, any isoniazid (INH) and rifampicin (RIF) resistance, monoresistance to INH and RIF, and multidrug-resistant TB (MDR-TB) in newly diagnosed and previously treated patients with TB. Results: A total of 24 studies with 18,908 patients with TB were included in the final analysis. The weighted pooled prevalence of any anti-TB drug resistance was 14.25% (95% confidence interval (CI): 7.05–21.44%)), whereas the pooled prevalence of any INH and RIF resistance was found in 15.62% (95%CI: 6.77–24.47%) and 9.75% (95%CI: 4.69–14.82%) of patients with TB, respectively. The pooled prevalence for INH and RIF-monoresistance was 6.23% (95%CI: 4.44–8.02%) and 2.33% (95%CI: 1.00–3.66%), respectively. MDR-TB was detected in 2.64% (95%CI: 1.46–3.82%) of newly diagnosed cases and 11.54% (95%CI: 2.12–20.96%) of retreated patients with TB, while the overall pooled prevalence of MDR-TB was 10.78% (95%CI: 4.74–16.83%). Conclusions: In Ethiopia, anti-tuberculosis drug resistance is widespread. The estimated pooled prevalence of INH and RIF-monoresistance rates were significantly higher in this review than in previous reports. Moreover, MDR-TB in newly diagnosed cases remained strong. Thus, early detection of TB cases, drug-resistance testing, proper and timely treatment, and diligent follow-up of TB patients all contribute to the improvement of DR-TB management and prevention. Besides this, we urge that a robust, routine laboratory-based drug-resistance surveillance system be implemented in the country.

Magnitude, associated risk factors, and trend comparisons of identified tuberculosis types among prisons in Ethiopia: A systematic review and meta‐analysis

“…Ethiopia is one of the 27 nations with the highest burden of multidrug-resistant TB as well. [4][5][6] The frequency of TB among inmates has been estimated to be up to 100 times greater than in the general population. 7 The higher frequency of TB in prisons may be attributed to a variety of variables.…”

“…This ranking places Ethiopia fourth in Africa and tenth in the world. Ethiopia is one of the 27 nations with the highest burden of multidrug‐resistant TB as well 4–6 …”

Predictors of Treatment Outcome and Drug Resistance in Tuberculosis Patients at Yirgalem General Hospital, Sidama Region, South Ethiopia: A Retrospective Cohort Study

“…Access to accurate and timely diagnosis of TB is crucial for effective treatment [5]. However, many regions, especially low-and middle-income countries, still face challenges in accessing quality diagnostic tools, such as GeneXpert machines or culture-based methods [3]. This leads to delays in diagnosis and initiation of treatment as well as evaluation of treatment outcomes.…”

“…While signi cant progress has been made in TB surveillance, there are still some important gaps in knowledge that need to be addressed. Some of a few areas where knowledge gaps exist in TB surveillance include underreporting and case detection, DR-TB surveillance, pediatric TB surveillance, timeliness of data, sub national and marginalized populations, and integration of data sources [3]. TB is known to be underreported, particularly in low-resource settings.…”

Analysis of drug resistance in pulmonary tuberculosis patients with positive sputum tuberculosis culture in Northeast China

“…Research has shown that there is widespread resistance to antituberculosis drugs. The prevalence rate of resistance to Isoniazid (INH) and Rifampicin (RIF) is significantly higher than previously reported, and there is still a high proportion of newly diagnosed cases with multidrug-resistant tuberculosis (Reta et al, 2022). Drugresistant tuberculosis has increased the burden of global antimicrobial drug resistance, resulting in significant medical care expenditure and resource consumption in affected countries (Liang et al, 2022;Liebenberg et al, 2022).…”